NASDAQ:MESO Mesoblast Q2 2026 Earnings Report $14.86 +0.34 (+2.36%) As of 01:34 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Mesoblast EPS ResultsActual EPS-$0.16Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMesoblast Revenue ResultsActual Revenue$25.67 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMesoblast Announcement DetailsQuarterQ2 2026Date1/29/2026TimeBefore Market OpensConference Call DateWednesday, January 28, 2026Conference Call Time6:00PM ETConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Mesoblast Earnings Headlines3 reasons why this ASX biotech stock could double in valueMay 11, 2026 | fool.com.auHow Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment StoryMay 2, 2026 | finance.yahoo.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 21 at 1:00 AM | Paradigm Press (Ad)Mesoblast Ramps Up Ryoncil Sales, Advances Late-Stage Cell Therapy PipelineApril 29, 2026 | tipranks.comMesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 MillionApril 29, 2026 | globenewswire.comA big milestone for this ASX biotech. Here's why the share price is movingApril 29, 2026 | msn.comSee More Mesoblast Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mesoblast? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mesoblast and other key companies, straight to your email. Email Address About MesoblastMesoblast (NASDAQ:MESO) is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective. The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease. In addition, Mesoblast’s lead investigational candidate, remestemcel-L, is in late-stage development in the United States for the treatment of pediatric patients with steroid-refractory acute graft-versus-host disease. Beyond these programs, Mesoblast maintains a diversified pipeline targeting heart failure, low back pain due to disc degeneration, and other immune-driven disorders, with multiple Phase 2 and Phase 3 trials underway. Headquartered in Melbourne, Australia, with a major corporate office in New York City, Mesoblast operates research and manufacturing facilities across North America, Europe, and the Asia–Pacific region. The company collaborates with strategic partners and regulatory authorities worldwide to advance its programs, ensuring broad geographic reach in both clinical development and commercial distribution. Under the leadership of founder and CEO Dr. Silviu Itescu, Mesoblast emphasizes rigorous clinical research, regulatory compliance, and scalable manufacturing processes. The company’s management team combines expertise in cell biology, clinical development, and partnership licensing to support its mission of bringing transformative therapies to patients with high unmet medical needs.View Mesoblast ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingTarget Shows Strengths, But Analysts Want to See MoreFreight Boom: The Hormuz Blockade PaydayTJX Companies Fires on All Cylinders With 9% Revenue GrowthAnalog Devices Provides Much-Needed Pullback: How Low Can It Go?USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal LoomsFrom Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
